StockNews.AI
ORGO
StockNews.AI
204 days

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025

1. Organogenesis will report Q4 and FY2024 results on February 27. 2. Management will host a call to discuss financial results and provide updates. 3. The conference call is scheduled for 5:00 p.m. Eastern Time.

Earnings
+1.54%Current Return
VS
-0.75%S&P 500
$3.5601/27 07:33 AM EDTEvent Start
$3.61501/28 02:11 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings reports typically have uncertain effects on stock prices, depending on results.

How important is it?

Earnings results could significantly influence investor perception and stock price volatility.

Why Short Term?

Immediate impact expected as investors react to the Q4 results announcement.

Related Companies

ORGO
CANTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2024 financial results will be reported after the market closes on Thursday, February 27th. Management will host a conference call at 5:00 p.m. Eastern Time on February 27th to discuss the results of the quarter and fiscal year, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year. About Organogenesis Holdings Inc. Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.

Related News